Engage early, design once: turning early-phase trials into a program strategy

In early clinical development, the fundamental mandate was once straightforward: establish initial safety, characterize pharmacokinetics (PK), and confirm target engagement. Checking these boxes quickly and cheaply was sufficient to screen out non-viable assets and protect capital. 

That baseline no longer holds. Driven by capital constraints and shifting investor expectations, Proof of Concept (POC) has fundamentally broadened. Early data must now prove biological, regulatory, and commercial viability simultaneously. For emerging biotechs, early data must be compelling enough to secure non-dilutive licensing, a major partnership, or acquisition before cash runways expire. For large pharma, it requires high-confidence filtering to balance internal pipelines where speed to market dictates survival. 

Yet traditional engagement models remain transactional. When sponsors view a CRO merely as a downstream executor — handing over a finalized protocol locked by internal teams or key opinion leaders (KOLs) — vital efficiencies are lost. By the time execution begins, the opportunity to optimize the broader program has passed. The result is often a technically sound study delivered too late, and in too much isolation, to de-risk the asset effectively. 

To achieve credible POC faster and more cost-effectively, sponsors must pivot from single-study execution to an integrated program strategy based on four foundational pillars.

1. Contain costs with upfront cross-functional collaboration 

A common objection among capital-constrained biotechs is that engaging multidisciplinary advisory services early adds unnecessary overhead to an already tight budget. In practice, the opposite is true: cutting corners during early planning frequently leads to expensive downstream protocol amendments, recruitment delays, and redundant studies. 

Engaging an integrated Asset Development Team that unites medical, statistical, regulatory, translational medicine, and clinical pharmacology expertise pressure-tests the asset's clinical hypothesis before protocols are locked. 

Cross-functional teams de-risk protocols by evaluating selection criteria, dose-escalation schemes, and cohort sizing to ensure studies yield decision-grade data using the leanest possible sample sizes. Integrating biomarker strategy and regulatory consulting from day one ensures that Phase I endpoints directly support Phase II go/no-go milestones and regulatory filings. 

Treating trial design as a strategic discipline upfront removes months of operational drag during execution.

2. Compress timelines via multi-objective master protocols

Modern early-phase programs should avoid running isolated Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), and special population studies sequentially. Instead, key secondary objectives—such as food effect, ethnobridging, organ impairment, and drug-drug interactions (DDIs)—can be synthesized into adaptive master protocols. 

For example, a preliminary food-effect read can be captured efficiently by re-dosing an existing SAD cohort alongside a standardized meal, delivering statistical adequacy without requiring a separate study. Model-Informed Drug Development (MIDD) allows teams to utilize predictive modeling, and continuous PK/PD simulation allows them to refine starting doses and dose-escalation steps between cohorts dynamically, significantly reducing safety review windows.

Case in Point: A sponsor recently approached Parexel with a development plan that scheduled six standalone DDI studies alongside redundant preclinical testing. By engaging holistically early in the drafting stage, our teams consolidated the interaction objectives into an integrated protocol, eliminated unneeded preclinical work, and accelerated the development timeline by roughly 12 months. 

3. Bring patients in earlier to accelerate proof of concept

Relying exclusively on healthy volunteer (HV) cohorts in First-in-Human (FIH) trials limits the early readout to basic safety and tolerability. While HV cohorts remain essential for clean baseline PK, running a parallel patient arm captures early biological activity without confounding healthy data.

Demonstrating measurable clinical activity in early phases provides a tangible value inflection point for subsequent financing or out-licensing discussions with investors and partners. Early patient cohorts build active working relationships with Phase II KOL investigators and clinical sites well ahead of later-stage trials.

Case in Point: For an early-phase dyslipidemia compound, running concurrent healthy volunteer and patient cohorts rather than sequential studies compressed the overarching development timeline by approximately 11 months.

To balance specialized early-phase monitoring with real-world patient access, sponsors can leverage a lean, early-phase-led operating model. Where specialized Early Phase Clinical Units (EPCUs) manage intensive PK/PD sampling, external clinical networks can be activated in a "wraparound" framework to source rare or complex patient cohorts without building costly late-phase infrastructure. For a recent rare-disease program, this approach enabled international patients to be flown to a central Parexel EPCU for dosing and intensive monitoring before returning home to their primary treating physicians—rapidly capturing high-value clinical data while significantly expanding trial access.

4. Optimize startup by pursuing a tiered global footprint 

In patient-enriched early-phase programs, recruitment logistics often present a larger bottleneck than the underlying science. Harmonizing operations across specialized units in multiple regulatory jurisdictions, such as the U.S., UK, and Europe, creates the logistics agility needed to pivot when local geopolitical or regulatory hurdles arise.

To maximize recruitment velocity, sponsors should implement a deliberate, two-tiered site strategy:

Tier 1 (Rapid-Activation Sites): Specialized centers with streamlined activation workflows rapidly hit First Site Initiated (FSI) and First Patient In (FPI) milestones, securing early momentum and stakeholder confidence.

Tier 2 (High-Volume Enrollment Hubs): Broader regional centers sustain long-term patient volumes. In therapeutic areas such as oncology, incorporating emerging high-performing regions (including vetted centers in Eastern Europe, such as Moldova and Georgia) provides access to treatment-naive patient pools and significantly shorter startup timelines while maintaining zero-deviation compliance and data integrity. 

Designing for faster go/no-go decisions 

Speed in early clinical development is meaningless if it does not drive value. Terminating an unviable asset or failing indication early preserves vital capital; rapidly advancing a winning molecule secures a competitive market entry. 

Achieving true speed to value requires establishing explicit decision-milestone criteria—defining exact biomarker thresholds, exposure levels, and stopping rules—before the first participant is dosed. By combining early cross-functional challenge, integrated master protocols, and a flexible global operating network, drug developers can replace transactional execution with a program strategy built to deliver clear, unassailable decisions.

Explore more episodes